As you can imagine, more people are reading The Jerusalem Post than ever before.
However, traditional business models are no longer sustainable and high quality publications,
Like ours, we are forced to look for new ways to move forward. Unlike many other news organizations,
We have not built a payment wall. We want to keep our journalism open.
and accessible and able to continue providing news.
and analysis from the front line of Israel, the Middle East and the Jewish world.
As one of our loyal readers, we ask you to be our partner.
For $ 5 a month, you will receive access to the following:
- A user experience almost completely free of ads.
- Access to our Premium Section
- Content of the award-winning Jerusalem Report and our monthly magazine to learn Hebrew – Ivrit
- A new ePaper with the newspaper as it appears printed in Israel
Help us grow and continue telling the story of Israel to the world.
Ronit Hasin-Hochman, CEO of Jerusalem Post Group
Yaakov Katz, Editor in Chief
UPGRAD YOUR JPOST EXPERIENCE FOR $ 5 PER MONTH
Show me later
November 27: Teva Pharmaceutical Industries Ltd is recalling certain combinations of valsartan, a medication for blood pressure, after the detection of a possible cancer-causing impurity, the last worldwide recall of this drug.
The Israeli pharmaceutical company will remember all batches of combined tablets of amlodipine-valsartan and amlodipine-valsartan-hydrochlorothiazide due to an impurity in an ingredient made by a Mylan unit in India, the United States Food and Drug Administration said on Tuesday ( FDA). (http://bit.ly/2DOBSfu)
Last week, the European Union effectively banned https://www.reuters.com/article/us-mylan-valsartan-united-states/mylan-recalls-batches-of-blood-pressure-medicine-in-us-idUSKCN1NP2I3 sales of valsartan manufactured by the Mylan India unit after it was discovered that some batches contained the same impurity, N-nitrosodiethylamine.
Teva has not received any reports of adverse events that indicate a possible link or exposure to valsartan, said the health regulator.
Patients are advised to continue taking their medications, as the risk of harm may be greater if the treatment is stopped immediately without comparable alternative treatment, the FDA said.
Join Jerusalem Post Premium Plus now for just $ 5 and update your experience with a website without ads and exclusive content. Click here >>